Biomarkers and translational research and precision medicine

20P - ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)

Authors
  • Gaia Griguolo (Bellinzona, Switzerland)
  • Fara Brasó-Maristany (Barcelona, Spain)
  • Tomás Pascual (Barcelona, Spain)
  • Nuria Chic (Barcelona, Spain)
  • Maria Vidal (Barcelona, Spain)
  • Barbara Adamo (Barcelona, Spain)
  • Tommaso Giarratano (Padova, Italy)
  • Maria Vittoria Dieci (Padova, Italy)
  • Valentina Guarneri (Padova, Italy)
  • Aleix Prat (Barcelona, Spain)
Speakers
  • Gaia Griguolo (Bellinzona, Switzerland)

Previous ePoster
19P - The clinical impact of substituting multigene assays: Comparative clinical analysis of PAM50-ROR versus 21-gene assay

Next ePosters
25P - Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard)
30P - Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
33P - Germline PALB2 heterozygous mutations in breast cancers: Haploinsufficiency paradigm
34P - Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor and synchronous axillary lymph node metastases in 159 breast cancer patients - indicating tumoral heterogeneity
35P - Downregulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in breast cancer: A new insight into the mechanism of induction of antitumor immunity
No ePoster preview available
36P - Endocrine implications in male breast cancer in Bulgaria
38P - Defining the physiological miRNA landscape in nipple aspirate fluid
40P - WNT, Hedgehog and NOTCH signaling pathways in triple negative breast cancer with high and low content of cancer stem cells
42P_PR - Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study
43P - CIP2A as a novel target to combat basal like breast cancer